Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | HTR2C | P28335 | 3/20 | 0.67 |
| ▸ | HTR7 | P34969 | 3/20 | 0.67 |
| ▸ | HTR6 | P50406 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9534623 | 0.99 | HTR2A (0.68) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9869610 | 0.97 | HTR2A (0.67) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9396999 | 0.96 | HTR2A (0.69) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL27737572 | 0.93 | HTR2A (0.65) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9229261 | 0.90 | HTR2A (0.72) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL10712477 | 0.89 | HTR2A (0.71) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL10577348 | 0.89 | HTR2A (0.71) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16481601 | 0.88 | HTR2A (0.71) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14318600 | 0.87 | HTR2A (0.81) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4981971 | 0.86 | HTR2A (0.67) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| CN-101384581-B | Benzoyl-piperidine derivatives as 5HT2/D3 modulators | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | disclosed |
| US-8415350-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| CN-101384581-A | Benzoyl-piperidine derivatives as 5HT2/D3 modulators | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| EP-0377528-B1 | Piperidines, process for their preparation and pharmaceutical compounds containing them | LIPHA (FR) | 1993-12-08 | — | — | EP | disclosed |
| EP-0184258-B1 | NOVEL DERIVATIVES OF HYDROXY- OR AMINO-SUBSTITUTED (PIPERIDINYLALKYL)QUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-05-06 | — | — | EP | disclosed |
| US-5001134-A | Piperidines, processes of preparation and medications containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1991-03-19 | — | — | US | disclosed |
| EP-0377528-A1 | Piperidines, process for their preparation and pharmaceutical compounds containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1990-07-11 | — | — | EP | disclosed |
| US-4665075-A | ANTISEROTONINE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-05-12 | — | — | US | disclosed |
| EP-0184258-A2 | Novel derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR2C | HTR2A 1/4885KDM4E 1738/4885CYP1A2 398/4885 |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | HTR2A 1/4885KDM4E 1738/4885CYP1A2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.